What is the purpose of this trial?The goal of lower limb rehabilitation after stroke is recovery of independent walking at home and in the community. Few stroke survivors achieve this goal. Suboptimal outcomes are due to the serious and intransigent nature of movement impairments caused by stroke and the scarcity of feasible and effective therapies that restore movement lost to stroke. Our team has developed a novel exercise intervention called CUped (pronounced cupid, like the Roman god) to address barriers to recovery and improve walking after stroke. CUped is so called because it compels use of the paretic limb during a movement that resembles pedaling. This project will examine safety, acceptability, and tolerance to CUped, characterize its therapeutic effects, and identify dose-response relationships. Results will provide preliminary data for an R01 to support a randomized controlled trial (RCT). CUped is designed to help stroke survivors recover lower limb movement lost to stroke, thereby improving walking. It is intended to be used as an adjunct to gait training. CUped uses a robotic technology that eliminates compensatory movements that interfere with recovery, compels use of the paretic lower limb, and targets 3 key movement impairments caused by stroke: decreased muscle output from the paretic limb, inappropriate paretic muscle timing, and abnormal interlimb coordination. Exercise is done in sitting which enables high repetition practice. Like walking, CUped requires continuous, reciprocal use of both lower limbs; effects are likely to transfer to walking. The risk-reward profile of this proposal is ideal for an R21, which is an NIH funding opportunity intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. CUped is a novel therapy grounded in a physiologic premise and based on prior observations from our laboratory. The investigators have pilot data suggesting that CUped fulfills its design specifications, and this study will be the first to test its therapeutic effects. In this Stage 1 rehabilitation trial, The investigators will support or quickly refute the hypothesis that CUped is safe, acceptable, and capable of eliciting a therapeutic response in stroke survivors. The investigators will also examine tolerance to CUped and dose-response effects. If our hypotheses are supported, the investigators will be poised to run an RCT to isolate the effects of CUped and compare them to standard care. Future work will investigate physiologic mechanisms underlying the effects of CUped.
Will I have to stop taking my current medications?The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your healthcare provider.
What data supports the effectiveness of the treatment CUped for stroke recovery?Research suggests that early mobilization and physical activity, such as using a cycle ergometer or feedback from a Smart watch, can improve recovery after a stroke by enhancing mobility and functional activities. These findings imply that treatments promoting physical activity, like CUped, may be beneficial for stroke recovery.
12345 Is the CUped Exercise for Stroke Recovery generally safe for humans?Exercise after a stroke is generally considered safe when properly supervised and tailored to the individual's condition. Safety guidelines emphasize the importance of pre-participation screening and monitoring to prevent adverse events, especially in the early phases of stroke recovery.
678910 How does the CUped Exercise treatment for stroke recovery differ from other treatments?The CUped Exercise treatment for stroke recovery is unique because it involves early bedside arm and leg cycle ergometer exercises, which may enhance sitting and standing abilities more effectively than routine physiotherapy. This approach focuses on early intervention and specific repetitive exercises, which are not typically emphasized in standard stroke recovery treatments.
511121314